Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom’s Macroglobulinemia in the Community Setting
FLORHAM PARK, N.J., Jan. 11, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a partnership to advance the treatment of Waldenstrom’s macroglobulinemia (WM) in the community setting with American Oncology Network (AON), a leading oncology platform with an innovative model of physician-led, community-based oncology management, and its data arm subsidiary Meaningful Insights-BioTech Analytics (MiBA), a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners.
Related news for (CLRB)
- Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
- Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
- Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
- MoBot’s Stock Market Highlights – 06/04/25 10:00 AM
- Breaking News: MoBot’s Latest Update as of 06/04/25 09:00 AM